Operator

Good day, and welcome to the Design Therapeutics conference call. [Operator Instructions] Please note this call is being recorded. I would now like to turn the call over to Sean Jeffries, COO. Please go ahead.

Sean Jeffries
Chief Operating Officer

I'm Sean Jeffries, COO of Design Therapeutics. This presentation will contain forward-looking statements, including statements related to our development plans and other information that is not historical fact. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied by such forward-looking statements. For more information regarding these risks and uncertainties, please refer to the press release we issued today and the risk factors in our most recent quarterly report on Form 10-Q. It is my pleasure now to turn the call over to Design Therapeutics CEO, Pratik Shah.

Pratik Shah
Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson

Thank you. On behalf of Design Therapeutics, I am delighted to announce an earlier-than-anticipated readout on our RESTORE-FA study, a multiple ascending dose study in patients with Friedreich Ataxia. The results we will share are based on 4 weeks of dosing from IV once weekly, conducted at 4 dose levels with a total of 16 patients in the